Sheetal Sapale, VP, commercial, Pharmarack, said four key therapy segments - cardiac, anti-infectives, gastro and respiratory - have driven the growth of the market by showing "excellent" value growth. "Growth has slowed down in many therapies in July, but the core therapies have not degrown. The therapies with seasonal diseases are growing in double digits. They have pulled up the growth of the market as they have made significant contributions to IPM," she added.
